AccessibilityHelpAbout Us
PharmaCielo logo

PharmaCielo(TSXV) PCLO

Market CapCA$11.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 Year-96%
1 Year+11%
1 Month-17%
CA$0.05
-16.67%
-0.01Today
PharmaCielo last closing stock price
MetricPriceDate
Last closeCAD 0.052026-09-15
PharmaCielo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.09%CAD 0.062026-09-08
1 month-16.67%CAD 0.062026-08-14
3 month-41.18%CAD 0.092026-06-17
Year to date+11.11%CAD 0.052025-08-05
1 year+11.11%CAD 0.052025-08-05
3 year-79.59%CAD 0.252023-09-15
5 year-96.03%CAD 1.262021-09-16
Since inception-99.15%CAD 5.852019-01-18

PharmaCielo Financials at a Glance

Market Cap

CA$11.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$3.60M

Net Income (TTM)

-CA$3.71M

EPS (TTM)

-CA$0.02

P/E Ratio

-2.69

Dividend

CA$0.00

Beta (Volatility)

-0.19 (Low)

Price

CA$0.05

Volume

33,355

Open

CA$0.05

Previous Close

CA$0.05

Daily Range

CA$0.05 - CA$0.05

52-Week Range

CA$0.04 - CA$0.17

Estimated Earnings Date

Nov 26, 2026

PCLO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PharmaCielo

PharmaCielo Ltd. is a leading company in the cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts. The company operates primarily in Canada and Colombia, providing a range of medicinal products and telemedicine software to various clients, including health and wellness manufacturers and pharmacies.

Products and Services
  • Pharmaceutical-grade cannabis extracts, including THC
  • Telemedicine software solutions for healthcare providers
  • Partnerships with health and wellness product manufacturers
Growth Outlook
  • Expansion into new markets is anticipated to drive revenue growth
  • Strategic partnerships enhance product offerings and market reach
  • Increasing demand for cannabis-based products supports long-term growth
Financial Highlights
  • Recent quarterly revenue of 1,390,077 CAD shows significant growth
  • Trailing twelve months (TTM) gross profit margin stands at 37.2%
  • Operating income for Q2 2026 reported at -539,327 CAD
PharmaCielo Ltd. is positioned in the rapidly growing cannabis industry, focusing on high-quality products and innovative solutions. The company's strategic partnerships and market expansion efforts are expected to enhance its competitive edge. Recent financial performance indicates a positive trajectory, with notable revenue growth in the latest quarter. However, the company continues to navigate challenges related to operating income, which reflects the need for ongoing operational improvements. Overall, PharmaCielo presents an intriguing opportunity for investors interested in the evolving cannabis market.
AI Generated • Sep 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Marc Lustig, MBA

Website

www.pharmacielo.com

Headquarters

Toronto, ON M5C 1P1, CA

PCLO Financials

Key Financial Metrics (TTM)

Gross Margin

37.20%

Operating Margin

-82.00%

Net Income Margin

-103.08%

Return on Equity

28.59%

Return on Capital

-116.13%

Return on Assets

-29.14%

Earnings Yield

-37.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$11.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

221.00M

Volume

33.35K

Avg. Volume

37.87K

Financials (TTM)

Gross Profit

CA$1.34M

Operating Income

-CA$2.96M

EBITDA

-CA$317.50K

Operating Cash Flow

-CA$6.96M

Capital Expenditure

CA$8.00

Free Cash Flow

-CA$6.96M

Cash & ST Invst.

CA$77.50K

Total Debt

CA$18.21M

PharmaCielo Performance Analysis

PharmaCielo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31CAD 1,541,749-71.0%
20242024-12-31CAD 3,479,797125.7%
20252025-03-31CAD 3,173,318-8.8%
20262026-03-31CAD 2,536,235-20.1%
PharmaCielo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30175.6%
Q42025-12-31-31.8%
Q12026-03-3118.5%
Q22026-06-3093.5%
PharmaCielo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31CAD -0.105.8%
20242024-12-31CAD -0.05-47.5%
20252025-03-31CAD -0.0722.1%
20262026-03-31CAD -0.02-70.9%
PharmaCielo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-7.2%
Q42025-12-31129.7%
Q12026-03-31-395.5%
Q22026-06-30-7.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$1.39M

+331.0%

Gross Profit

CA$603.40K

+4615.2%

Gross Margin

43.41%

N/A

Market Cap

CA$11.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$41.23K

N/A

Employees

268

N/A

Net Income

-CA$1.44M

-10.5%

EBITDA

-CA$351.84K

+19.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$77.50K

+1084.8%

Total Debt

CA$18.21M

-12.4%

Accounts Receivable

CA$1.06M

+44.7%

Inventory

CA$1.75M

+16.6%

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$18.21M

-12.4%

Return on Assets

-29.14%

N/A

Return on Invested Capital

27.62%

N/A

Free Cash Flow

-CA$227.86K

-110.8%

Operating Cash Flow

-CA$227.86K

-110.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KHRN.VKhiron Life Sciences Corp.
CA$0.04+0.00%
VIVO.TOVIVO Cannabis Inc.
CA$0.03+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$102.32+1.18%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$51.10-1.22%
INTCIntel
$97.14-0.05%
NOKNokia
$9.84+1.97%

Questions About PCLO

What is the current price of PharmaCielo?

PharmaCielo is trading at CA$0.05 per share.

What is the 52-week range for PharmaCielo?

Over the past 52 weeks, PharmaCielo has traded between CA$0.04 and CA$0.17.

How much debt does PharmaCielo have?

As of the most recent reporting period, PharmaCielo reported total debt of CA$18.21M.

How much cash does PharmaCielo have on hand?

PharmaCielo reported CA$77.50K in cash and cash equivalents in its most recent financial results.

What is PharmaCielo’s dividend yield?

PharmaCielo does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services